Antipain agent shrinks oral cancers without damaging healthy tissue
July 25, 2014 -- Mouse models of human oral cancer treated with capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, according to a study in Oral Oncology. Capsazepine's anticancer effects may stem from its ability to increase oxidative damage in tumors, Texas researchers said.
CEL-SCI expands head/neck cancer drug trial
July 25, 2014 -- CEL-SCI is expanding the phase III clinical trial of its investigational cancer immunotherapy therapy, Multikine, to the U.K., Austria, Turkey, and Sri Lanka. The company hopes to enroll 880 patients in 20 countries by the end of 2015.
CDC study: HPV vaccines could prevent most oropharyngeal cancers
July 23, 2014 -- Human papillomavirus (HPV) vaccines could prevent most oropharyngeal cancers in the U.S., according to a new Centers for Disease Control and Prevention (CDC) study in Emerging Infectious Diseases. The analysis of patients with oropharyngeal cancer found that most were HPV-positive, especially for HPV types 16 and 18, and the majority of patients were white men.
Advaxis, MedImmune partner on clinical trial
July 22, 2014 -- Advaxis, a biotechnology company that develops cancer immunotherapies, has entered a clinical trial collaboration with MedImmune, the biologics research and development arm of AstraZeneca.
Investigational drug may benefit head/neck cancer patients
July 14, 2014 -- The investigational drug dacomitinib may benefit patients with recurrent or metastatic squamous cell carcinoma of the head and neck, according to the results of phase II clinical trial by researchers in South Korea.
ACS awards $1.7M to study racial disparities in HNC patients
July 10, 2014 -- The American Cancer Society (ACS) has awarded a $1.7 million grant to Philadelphia researchers to investigate factors that may contribute to the racial disparities seen among those diagnosed and treated for head and neck cancers (HNC).
Aspirin can help battle head/neck cancer
Aspirin appears to offer significant protection against head and neck (HNC) cancer, according to a study in the British Journal of Cancer. Regular aspirin use was associated with a 22% reduction in HNC and seems to be particularly effective in preventing laryngeal cancer.